Eikon Therapeutics, Inc. (EIKN)

Market Cap	485.08M
Revenue (ttm)	n/a
Net Income	-342.06M
EPS	-32.19
Shares Out	54.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,292
Open	9.78
Previous Close	9.78
Day's Range	8.73 - 9.83
52-Week Range	7.90 - 17.40
Beta	n/a
Analysts	Buy
Price Target	24.80 (+176.79%)
Earnings Date	May 11, 2026

About EIKN

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent W...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2026
• Employees: 384
• Stock Exchange: NASDAQ
• Ticker Symbol: EIKN
• Website: https://eikontx.com

Analyst Summary

According to 6 analysts, the average rating for EIKN stock is "Buy." The 12-month stock price target is $24.8, which is an increase of 176.79% from the latest price.

Price Target

$24.8

(176.79% upside)

Analyst Consensus: Buy